Acurx Pharmaceuticals Inc...
(ACXP)
undefined
undefined%
At close: undefined
0.86
1.08%
After-hours Dec 13, 2024, 04:00 PM EST
Company Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections.
Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections.
The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae.
Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Acurx Pharmaceuticals Inc.
Country | United States |
IPO Date | Jun 25, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 4 |
CEO | David P. Luci CPA, Esq., J.D. |
Contact Details
Address: 259 Liberty Avenue Staten Island, New York United States | |
Website | https://www.acurxpharma.com |
Stock Details
Ticker Symbol | ACXP |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001736243 |
CUSIP Number | 00510M104 |
ISIN Number | US00510M1045 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
David P. Luci CPA, Esq., J.D. | Co-Founder, President, Chief Executive Officer, Corporate Secretary & Director |
Robert G. Shawah CPA, CPA | Co-Founder & Chief Financial Officer |
Robert J. DeLuccia | Co-Founder & Executive Chairman |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 13, 2024 | 8-K | Current Report |
Nov 12, 2024 | 10-Q | Quarterly Report |
Aug 09, 2024 | 8-K | Current Report |
Aug 08, 2024 | 10-Q | Quarterly Report |
Jun 18, 2024 | 4 | Filing |
Jun 18, 2024 | 4 | Filing |
Jun 18, 2024 | 4 | Filing |
Jun 18, 2024 | 4 | Filing |
Jun 18, 2024 | 4 | Filing |
Jun 17, 2024 | 8-K | Current Report |